The short version
- Why people research itFocus, memory, neuroprotection, mood and stress resilience.
- What the evidence isNo human trials: development stopped at preclinical, so the ceiling on any claim here is a rodent model — and these transfer poorly.
- What to watchA seizure, or fainting with a skipped heartbeat.
How PE-22-28 works
TREK-1 potassium-channel blocker derived from spadin — promotes neurogenesis with fast-acting antidepressant effects in models.
Start with where the molecule comes from, because it is not what the name suggests. Sortilin, also called neurotensin receptor-3, is made as a precursor and cleaved by the protease furin in the late Golgi.
It was not designed. It was salvaged from what survived. The group started from spadin's own blood degradation products and built the 7-residue peptide out of the piece that was still there after the parent had been chewed up Djillani 2017.
- Injectable
On the goal map: BDNF & neurotrophic signaling (Focus, memory & cognition)
Research on PE-22-284 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Human clinical evidence
No human trials: development stopped at preclinical, so the ceiling on any claim here is a rodent model — and these transfer poorly.
No completed human trial
Correlative data
Very limited community use — it is a recent research compound with almost no practical record, and what exists is a handful of self-reports about mood.
How the mechanism reads
A spadin analog that blocks the TREK-1 potassium channel. TREK-1 knockout mice show a depression-resistant phenotype, and blocking it produces antidepressant-like effects in rodents within days rather than the weeks SSRIs require.
Experimental, animal or cellThe speed is the interesting part mechanistically — a channel-level intervention does not need the receptor adaptation that makes conventional antidepressants slow. Whether that transfers to humans is entirely untested.
Mechanistic
Sources
- Djillani A, Pietri M, Moreno S, Heurteaux C, Mazella J, Borsotto M. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Frontiers in Pharmacology 2017 · PMID 28955242
- Mazella J, Petrault O, et al. Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. PLoS Biology 2010 · PMID 20405001
- Djillani A, Mazella J, Heurteaux C, Borsotto M. Fighting against depression with TREK-1 blockers: Past and future. A focus on spadin. Pharmacology and Therapeutics 2019 · PMID 30291907
- Pietri M, et al. First evidence of protective effects on stroke recovery and post-stroke depression induced by sortilin-derived peptides. Neuropharmacology 2019 · PMID 31325429
- Mazella J, Borsotto M, Heurteaux C. The Involvement of Sortilin/NTSR3 in Depression as the Progenitor of Spadin and Its Role in the Membrane Expression of TREK-1. Frontiers in Pharmacology 2018 · PMID 30670975
PE-22-28 safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Seizure history: blocking the TREK-1 potassium brake lets neurons fire more easily.
- Bipolar disorder: an antidepressant-type neurogenic effect can switch mood toward mania.
- Age under 25 with depression or suicidal thoughts: no human safety data exist.
- Heart rhythm disorder: potassium channel blockers can change cardiac repolarization.
- Pregnancy: TREK-1 channels shape fetal nerve development, so blocking them is untested.
What’s expected
- Human effects are unknown; only animal data support fast-acting mood lift.
- Alert, slightly wired feeling if it works as a TREK-1 blocker.
- Redness or soreness at the application spot.
Watch for
- A seizure, or fainting with a skipped heartbeat.
- Racing heart or palpitations.
- Several nights of little sleep with high energy.
- Worsening mood or self-harm thoughts.
Labs that tell you it’s working
- Comprehensive Metabolic Panel (CMP)
- Magnesium
- TSH (Thyroid-Stimulating Hormone)
- Cortisol
PE-22-28 is a spadin analog that blocks TREK-1 potassium channels; only animal data exist, so every line is mechanism prediction.
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
PE-22-28 FAQ4 common questions
- Is PE-22-28 approved for human use?
- No. PE-22-28 is a research compound. No completed randomized human trial has given it yet.
- What is PE-22-28 researched for?
- Focus, memory, neuroprotection, mood and stress resilience.
- Which labs show whether it's doing anything?
- Comprehensive Metabolic Panel; Magnesium; TSH; Cortisol: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for PE-22-28: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.




